SignalMacro

CytoMed Therapeutics receives Nasdaq notice over minimum bid price deficiency

Nasdaq minimum bid price deficiency notice triggers delisting risk for CytoMed Therapeutics.

What changed

Nasdaq minimum bid price deficiency notice triggers delisting risk for CytoMed Therapeutics.

Why it matters

Nasdaq minimum bid price deficiency notice triggers delisting risk for CytoMed Therapeutics. — impact context not separately stored; see What changed.

Sources

seekingalpha